Latest insight from Medicines Law & Policy

The Waiver that Wasn’t: Is the pharma lobby responsible?

Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...

TRIPS, technology transfer and access to pandemic countermeasures: What the WHO  Pandemic Treaty must...

The scrambling for access to Covid-19 vaccines by developing countries has reignited the debate on the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS)...

Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert...

Negotiators of a Pandemic Treaty should heed the recommendations, published 15 July in the BMJ Global Health, to design a fair global system for...

WTO Covid-19 TRIPS Decision: Some observations

This morning, 17 June at 5 AM the 12th World Trade Organization (WTO) Ministerial Conference (MC12) approved a package of decisions and declarations. The...

Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact

In October of 2020, 9 months into the pandemic, fearing conflicts over intellectual property (IP) related to medical measures to fight the pandemic,  India...

The US NIH will share technology with WHO to fight the pandemic

The US National Institutes of Health today committed to sharing several technologies with a World Health Organization body tasked with increasing access to Covid-19...

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).